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1001-106 Early Use of Beta-Blockade in Complicated Myocardial 
Infarction: The VALIANT Trial 
Robed M. Califf. Marc A. ffeffer, John J. McMurray. Aldo P. Maggiom, Jean-Lucien 
Rouleau, tars Kober, Frans J. Van de Wed, Jeffrey D. Leimberger. Marc Henis, Susan 
Edwards, Mary Ann Sellers, Helmut Drexler, Jiri Kvasnicka, Jiri Spat, Martin Myers, Eric 
J. Velazquez, Duke Clinical Research Institute, Durham, NC, Brigham & Women’s 
Hospital, Boston, MA 
Background: The early use of beta-blockers (EB) in myocardial infarction (MI) compli- 
cated by left ventricular dysfunction (LVD) or heart failure (HF) has been controversial, 
especially with intensive blockade of the renin-angiotensin system (RAS). 
Methods: The VALIANT trial randomized 14.808 patients with acute Ml and HFiLVD to 
valsartan, captopril, or both. The use of BB was not mandated. We divided patients by 
BB use at randomization (median 4.8 days post-MI) and compared baseline factors and 
outcomes. 
Resutts: The BB-treated patients (n=10,390; 70%) were younger and tended to be in a 
lower Killip class. Mortality 30 days after enrollment was lower in those treated with BB, 
even after adjusting for a risk model in the population (hazard ratio 0.74; 95% Cl 0.63. 
0.88). 
Conclusion : Although the trial did not mandate the use of BB, the rate of use was high 
and associated with lower mortality. even with high-intensity blockade of RAS. 
Characteristics and Outcomes by BB Use at Randomization 
Variable (median or %) 
Age, Y 
Male sex 
Prior Ml 
Diabetes 
Blood pressure, mm Hg 
Anterior Ml 
Killip class >I 
Ejecbon fraction, % 
Heart rate. bpm 
Stroke 
Mortality 
BB (n=10,390) No BB (nz4412) 
64 69 
70 66 
27 30 
21 27 
120/70 12of70 
61 55 
68 82 
34 33 
74 80 
0.7 1.1 
3.0 6.5 
1001-107 Effect of Gender on Strategies for Revascularization for 
Cardiogenic Shock 
Aaron D. Kuaelmass, Michael Mack, Sameer Mehta, Lynn G. Tarkington, Salvatore 
Battaglia, April W. Simon, Steven D. Cutler, Edmund R. Becker, Emory University. 
Atlanta, GA, Henry Ford Health System, Detroit, Ml 
Background: Mortality of patients with cardlogenic shock (CS) complicating acute myo- 
cardial infarction (AMI) remains markedly elevated. This study assesses the effect of 
gender and revasculawation on in-hospital survival. Method: The HCA Casemix Data- 
base, a dataset on all patients discharged from the 195 HCA Hospitals for the period Jan- 
uary 1998 through March 2001, was analyzed. The sample consisted of 3,651 male and 
2,591 female CS patients with a primary diagnosis of AMI. Logistic regression techniques 
were used to determine if the type of revascularization treatment (no intervention or con- 
servative therapy, thrombolytic only, PCI only, CABG only, or any combination of these 
therapies) CS patients received was associated with an increased mortality (male 
patients receivmg conservative therapy as the reference). 
Results: Male CS patients averaged 72 years of age and had higher rates of COPD, 
smoking, chronic liver disease, prior MI, and conduction disorders. Female CS patients 
were older (75 years) and had higher incidence of diabetes, chronic renal failure, PVD, 
and hypertension. Below are the odds ratios for mortality after adjusting for age and 
comorbidity. Conclusions: After risk adjustment, all repelfusion and revascularizatlon 
strategies confer substantial survival advantage (> 42%RR) for both male and female CS 
patients. Our data suggests that gender should not prevent utilization of thrombolytic or 
revascularization therapy in AMI complicated by cardiogenic shock. 
JACC March 19,2003 
Male Female 
Thrombolytic Only 
PCI Only 
CABG Only 
‘p=<o.ool 
0.575 (0.008) 0.484 (0.005) 
0.288 0.441’ 
0.369’ 0.405’ 
1001-108 Increased Risk of Adverse Outcomes With Proximal 
Culprit Artery Lesions in Acute Myocardial Infarction 
Juhana K&a, Sabina A. Murphy, Ajay J. Kirtane, Christopher P. Cannon, Elliott M. 
Antman, C. Michael Gibson, The TIMI Study Group, Brigham&Women’s Hospital, 
Boston, MA 
Background: Reduced flow and left anterior descending (LAD) artery culprit location 
have been associated with poorer outcomes following thrombolytic administration. We 
hypothesized that culprit lesion location in the proximal portion of the culprit artery would 
also result in poorer clinical outcomes compared to a distal location. 
Methods: Lesion location and clinical outcomes were evaluated in 2,536 patients from 
the TIMI 4, lOA, IOB, and 14 trials. 
Results: The majority of culprit lesions (78.4%, 1,987/2.536) were located proximally. 
Proximal lesions (lesions before or at the second major branch) were associated with a 
higher incidence of in-hospital death or recurrent myocardial infarction (Ml) when corn- 
pared to distal lesions (7.3% (14411,986) vs. 4.2% (23/549). p=O.Ol), and they tended to 
be associated with a higher rate of in-hospital death (4.1% (82/l ,986) vs. 2.6% (14/549). 
p=O.O86). In a multiple logistic regression model, the presence of a proximal lesion 
increased a patient’s risk of death or Ml (O.R. 1.8. p=O.O4, after adjustment for LAD loca- 
tion, epicardial flow and multivessel disease) In a quantitative analysis, the planimetered 
distance from the ostium to the LAD culprit lesion was shorter in patients who died or 
experienced recurrent MIS within 30 days (3.0 cm vs. 3.8 cm, p=O.Oll). This pattern was 
not evident for right coronary artery (RCA) or circumflex culprit vessels. In a multiple 
logistic regression model, the distance from the ostium to the LAD culprit lesion was 
associated with do-day death or recurrent MI (O.R. 0.79 per cm increase in distance 
down the artery; p=O.OOe). Conclusions: Independent of TIMI grade 3 flow and LAD 
location, a proximal culprit lesion location is also associated with an increased risk of 
adverse outcomes following thrombolytic administration, possibly due to a larger area of 
myocardium subtended. 
1001-109 Higher Platelet Counts Are Associated With Greater 
Thrombus Burden in Patent Arteries Following 
Thrombolytic Administration: A TIMI Angiographic 
Substudy 
‘C. Michael Gibson, Sabina A. Murphy, Graham C. Wang, Elliott M. Antman, Susan J. 
Marble, Rupal Kalapanda, Nicole Kraimer, Rosemary Markovic. Christopher P. Cannon. 
TIMI Study Group, Boston, MA, Brigham and Woman’s Hospital, Boston, MA 
Background: While dosing of many drugs is adjusted to a patient’s weight, little attention 
has focused on variations across patients I” the platelet count (pit). Methods: Data were 
obtained from 2,917 patients enrolled in the TIMI 4, lOA, lOB, 14 and 20 trials of ST ele- 
vation myocardial infarction (STEMI). Core laboratory angiographers were blinded to 
hematologic data. Results: Baseline platelet counts were higher in females and in pts < 
age 65 (p<O.OOOl; Table). Platelet counts were higher in patients with thrombus present 
(p=O.O002. Table) but did not differ by patency at 60 minutes following thrombolytic 
administration (p=NS). When restricted to those with an open artery at 60 minutes, plate- 
let counts were higher in the presence of thrombus (median plt = 253K in pts with throm- 
bus vs plt = 240K without thrombus. p=O.O006). There was no difference in hematocrit by 
thrombus presence (median 43.4 vs 43.1, p=NS). In a multivariate model that controlled 
for age, gender and patency, the presence of thrombus remained associated with higher 
platelet counts (p<O.OOl). Conclusions: In the setbng of STEMI, there are gender and 
age related differences in the platelet count. The presence of residual thrombus in the 
artery after restoration of patency is associated with higher platelet counts even after 
adjustment is made for these confounders. Further investigation of the role of platelet 
number and the number of GP llbllla receptors on each platelet (total receptor burden) 
may be warranted to optimize drug efficacy. 
Characteristic Characteristic Present Characteristic Absent p-value 
Female median = 263.5K. n=688 median = 237K, n=2229 ~0.0001 
Age ~65 median = 250K, n=l944 median = 232K. n=941 <0.0001 
TFG 2l3 median = 244K, 1~1240 median = 245K, n=376 0.41 
Thrombus median = 249K. n=942 median = 241K. n=1807 0.0002 
Platelet Count 
